Xintela AB (XINT) AI Stock Analysis

• Market Cap: kr295.61M
• Dividend Yield: N/A
• Average Volume (3M): 590.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 5303.85%
• EPS Growth: 55.59%
• Country: SE
• Employees: 21
• Sector: Technology
• Sector Strength: 79
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 665,798,030
• 10 Day Avg. Volume: 721,693
• 30 Day Avg. Volume: 590,899
• PEG Ratio: 0.11
• Price to Book (P/B): 15.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Xintela AB's stock is facing significant financial challenges, with persistent losses and negative equity being major concerns. The recent revenue growth is a positive sign but is overshadowed by the company's dependence on external financing and unprofitability. Technical indicators show a mixed outlook, while valuation metrics reflect the company's financial instability. Overall, Xintela AB requires substantial improvement to become a more attractive investment.

Xintela AB Business Overview & Revenue Model

Company Description

Xintela AB (XINT) is a biotechnology company based in Sweden that focuses on the development and commercialization of cell therapy products and targeted cancer treatments. The company leverages its proprietary marker technology, XINMARK, to identify and select specific cell types for therapeutic use, primarily in the fields of regenerative medicine and oncology. Xintela's core products and services revolve around stem cell-based therapies for osteoarthritis and other musculoskeletal disorders, as well as targeted antibodies for the treatment of aggressive cancers.

How the Company Makes Money

Xintela AB primarily generates revenue through the development and commercialization of its proprietary cell therapy products and targeted cancer treatments. The company earns money by partnering with pharmaceutical companies and research institutions to co-develop therapies, licensing its technology, and potentially through future product sales once regulatory approvals are secured. Significant factors contributing to its earnings include collaborative agreements, research grants, and strategic partnerships that support the advancement of its clinical programs. Additionally, Xintela may benefit from milestone payments and royalties from commercialized products developed using its technology.

Xintela AB Financial Statement Overview

Summary

Xintela AB shows potential with increased revenue, but persistent operating losses and negative equity highlight financial instability. The company's cash flow is highly dependent on financing activities, and the negative financial ratios suggest a need for structural financial improvements to achieve long-term sustainability.

Income Statement

Xintela AB has shown significant revenue growth from 2023 to 2024, increasing from SEK 78,000 to SEK 4,215,000. However, the company continues to face substantial losses with a negative net profit margin and EBIT margin due to high operating expenses. The gross profit margin is strong at 100% due to the low cost of revenue, but earnings remain negative, indicating profitability challenges.

Balance Sheet

The company has a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is technically zero due to no debt, but this is overshadowed by the negative equity. The equity ratio is also negative, reflecting more liabilities than assets, posing a risk to financial stability.

Cash Flow

Free cash flow improved slightly due to increased financing, but operating cash flow remains negative, indicating operational cash generation challenges. The company's reliance on external financing is significant, which could affect financial independence in the long-term.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.21M	78.00K	0.00	0.00	0.00
	Gross Profit
3.66M	78.00K	-3.79M	-3.50M	-3.57M
	EBIT
-39.45M	-57.24M	-69.06M	-43.56M	-33.90M
	EBITDA
-38.90M	-53.47M	-64.83M	-57.11M	-30.33M
	Net Income Common Stockholders
-39.19M	-54.08M	-66.22M	-58.93M	-52.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
16.68M	7.81M	8.34M	9.94M	33.60M
	Total Assets
24.80M	18.39M	24.52M	24.74M	48.51M
	Total Debt
0.00	0.00	0.00	0.00	10.90M
	Net Debt
-16.68M	-7.81M	-8.34M	-9.94M	-22.70M
	Total Liabilities
30.75M	14.02M	18.74M	20.80M	20.91M
	Stockholders Equity
-5.95M	4.38M	5.78M	3.95M	27.61M
Cash Flow		Free Cash Flow
-40.70M	-53.22M	-39.60M	-44.15M	-21.71M
	Operating Cash Flow
-40.70M	-53.12M	-39.49M	-42.89M	-21.33M
	Investing Cash Flow
0.00	-104.00K	-27.52M	-1.20M	-329.00K
	Financing Cash Flow
50.09M	51.79M	64.56M	20.43M	54.85M

Xintela AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Neutral. The current price of 0.43 is below the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.41, and above the 200-day MA of 0.41, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.43 is Neutral, neither overbought nor oversold. The STOCH value of 50.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:XINT.

Xintela AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$11.97B	10.08	-7.46%	2.96%	7.37%	-8.22%
XBRANE	54 Neutral	kr402.97M	―	-47.73%	―	45.52%	93.35%
NXTCL	47 Neutral	kr109.21M	―	-69.81%	―	-17.91%	22.80%
IMMU	44 Neutral	kr338.03M	―	-18.79%	―	―	21.85%
ACE	43 Neutral	kr531.98M	―	-138.29%	―	―	39.92%
XINT	43 Neutral	kr295.61M	―		―	5303.85%	55.59%
ISOFOL	36 Underperform	kr162.94M	―	-54.29%	―	-100.00%	-17.35%